Simple blood test may spot newborns at risk for lung trouble
NCT ID NCT07394322
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether measuring a substance called interleukin-6 (IL-6) in the blood can predict which newborns will develop meconium aspiration syndrome, a serious breathing problem. Researchers tested 120 full-term infants born with meconium-stained amniotic fluid. The goal was to see if IL-6 levels could serve as an early warning sign.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- serum interleukin-6 test
- What this could lead to
- If successful, this could help doctors identify newborns at risk for meconium aspiration syndrome early, allowing for quicker monitoring and care.
- What could go wrong
- This is a small, completed diagnostic study, not a treatment trial. The test may not be accurate enough for routine use, and results need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
120 people
The number who actually took part.
- Started
-
Jan 2023
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 minute to 72 hours
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * both genders (Males and females), term infants (above 37 gestational weeks), and born from ladies who have meconium-stained amniotic fluid. Exclusion Criteria: * Infants born to mothers suspected of having chorioamnionitis (leukocytosis, fever, early membrane rupture (above 18 hours), foul-smelling discharge, tachycardia in the mother or fetus, as well as a positive blood culture), * those without parental consent, * those with severe perinatal asphyxia (Stage two or three of hypoxic-ischemic encephalopathy findings according to Sarnat (6)), * those with severe chorioamnionitis, * those withcongenital abdominal malformations,
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Meconium aspiration syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Benha Faculty of Medicine
Banhā, 15312, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.